9 Tips for Avoiding Tax Season Cyber Scams 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Bank of Japan Eyes April Rate Hike Despite Inflation Dip, ING Says 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
